clinical trial · NCT07213674
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
Metastatic Castration-resistant Prostate CancerXaluritamigAbiraterone acetateDocetaxelCabazitaxel
brief summary
The primary objective of this study is to compare overall survival (OS) in participants receiving xaluritamig plus abiraterone against investigator's choice (docetaxel, cabazitaxel, or abiraterone).
started
Nov 28, 2025
primary completion
Jan 7, 2030
completion
Aug 30, 2032
last updated
Jun 18, 2026
official title
A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol